US.EW · Edwards Lifesciences

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.401644157369348,
        "turnoverUsdM": 205.07526,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.EW",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 81.06,
      "strength_details": {
        "ma_score": 1,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 4.8,
      "take_profit_price": 89.4075,
      "target_multiplier": 1.6,
      "technical_strength": 1.15,
      "take_profit_percent": 5
    },
    "positionPoints": 1.4,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.803288314738696,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 50.9,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 49.9,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 1
  },
  "market": {
    "ma20": 86.926,
    "ma50": 88.4808,
    "close": 85.15,
    "prevClose": 85.19,
    "avgVolume20": 3497200,
    "volumeRatio": 0.69,
    "changePercent": -0.05
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 1,
    "details": {
      "ret_5d": -0.013211264341175144,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 1,
      "vcp_bonus": 0,
      "vol_ratio": 0.6942664785232568,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.8983677291645172,
      "volat_points": 0,
      "day_range_pct": 0.021374045801526805,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 1,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 50.9,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.7,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 54,
        "contribution": 2.7
      },
      {
        "raw": 6,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 10.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 68,
        "contribution": 10.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7.2,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 72,
        "contribution": 7.2
      },
      {
        "raw": 15.8,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 52.67,
        "contribution": 15.8
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "checked",
  "standard110": {
    "rating": "避免",
    "result": 49.9,
    "details": [
      "基本面分析總分: 2.7/5分",
      "資金流分析總分: 6/20分",
      "市場環境分析總分: 10.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7.2/10分",
      "技術信號分析總分: 15.8/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.7,
      "資金流": 6,
      "市場環境": 10.2,
      "情緒分析": 6,
      "技術信號": 15.8,
      "風險管理": 7.2
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 3,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0.4,
          "turnoverUsdM": 205.07526,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 0.8,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.EW",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 2.4,
            "details": {
              "source": "twelvedata+fred",
              "vixClose": 16.39
            }
          },
          "trend": {
            "score": 4,
            "details": {
              "qqq": {
                "ma20": 727.77950075,
                "ma50": 716.81699944,
                "name": "QQQ",
                "close": 749.58002,
                "points": 2
              },
              "spy": {
                "ma20": 764.8284993999999,
                "ma50": 763.70219804,
                "name": "SPY",
                "close": 769.64001,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.401644157369348,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 2.4,
          "marketTrendPoints": 4
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 3,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 1.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142266550,
                "url": "https://finnhub.io/api/news?id=da0f8c9693d571ce918d448e54f2a4e1f344477545ea3925d87467465be4b61c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...",
                "category": "company",
                "datetime": 1789769713,
                "headline": "How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions"
              },
              {
                "id": 142260140,
                "url": "https://finnhub.io/api/news?id=e456714e92954de98b33d6053fadb104ecebefa6f418a514898827cc6f127659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...",
                "category": "company",
                "datetime": 1789755142,
                "headline": "Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion"
              },
              {
                "id": 142197743,
                "url": "https://finnhub.io/api/news?id=9b56623bc1072bd0de84cf62140ea790418711ad90edb1c273a8b5b42899b3ea",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "Edwards Lifesciences Corporation (EW) Deutsche Bank 2026 Healthcare Summit September 16, 2026 10:00 AM EDTCompany ParticipantsBernard Zovighian - CEO &...",
                "category": "company",
                "datetime": 1789563698,
                "headline": "Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript"
              }
            ],
            "raw_source": [
              {
                "id": 142614627,
                "url": "https://finnhub.io/api/news?id=8655f8ec1bb477449776d78501af9ab82fe6b743d6ab33f1f8d7997fe0bbe8ef",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/02/Doctors--Tablet-And-People-With-Discussi.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences earned FDA approval for its AUTUS pediatric heart valve, designed to expand as young patients grow.",
                "category": "company",
                "datetime": 1790937962,
                "headline": "Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve"
              },
              {
                "id": 142589114,
                "url": "https://finnhub.io/api/news?id=80eebecc20b73e3685f3c3092f41f338a5253af972377b06c0dc5ce304802ac8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/10/02/Bangkok--Thailand---July-2--2017nike-Cla.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Nike falls on weak revenue; Synaptics jumps on $123 ON deal; AsiaStrategy surges on tokenization pact; Mangoceuticals drops.",
                "category": "company",
                "datetime": 1790914563,
                "headline": "Nike, Synaptics And 3 Stocks To Watch Heading Into Friday"
              },
              {
                "id": 142563009,
                "url": "https://finnhub.io/api/news?id=b0ab83642594294ce72c45514fe4296905c2602deb7307b9dddd9eaf37adf90a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "IRVINE, Calif., October 01, 2026--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement.",
                "category": "company",
                "datetime": 1790886360,
                "headline": "Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients"
              },
              {
                "id": 142590120,
                "url": "https://finnhub.io/api/news?id=17619dfabefb34c722fa720a4545f003a4542ab1a2e12bc371a4dd0e88326aff",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with",
                "category": "company",
                "datetime": 1790872027,
                "headline": "Edwards Lifesciences Says FDA Approves AUTUS Size-Adjustable Valve, Surgical Pulmonary Valve Designed For Pediatric Patients With Congenital Heart Disease"
              },
              {
                "id": 142266550,
                "url": "https://finnhub.io/api/news?id=da0f8c9693d571ce918d448e54f2a4e1f344477545ea3925d87467465be4b61c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...",
                "category": "company",
                "datetime": 1789769713,
                "headline": "How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions"
              },
              {
                "id": 142260140,
                "url": "https://finnhub.io/api/news?id=e456714e92954de98b33d6053fadb104ecebefa6f418a514898827cc6f127659",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences has delivered a mixed share price story, with the stock up 18.4% over the past year but still down sharply over a 5 year span. This puts the focus squarely on what investors are paying for its future cash flows. With fresh policy news around its core heart valve franchise and a current share price of US$88.25, the key issue is whether the company’s cash generation can support where the stock trades today. Over 5 years the share price has declined 27.1%, which raises the...",
                "category": "company",
                "datetime": 1789755142,
                "headline": "Edwards Lifesciences (EW) Stock Looks Reasonable After Medicare TAVR Expansion"
              },
              {
                "id": 142251945,
                "url": "https://finnhub.io/api/news?id=37512db8dc48a1b609e465c892d8209fa7791765c124efa21b1a41a2ce7135c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The global interventional cardiology devices market is forecast to grow from USD 31.12 billion in 2026 to USD 42.39 billion by 2031, at a 6.4% CAGR. Growth is driven by rising cardiovascular disease, aging populations, demand for minimally invasive procedures, better healthcare access, and advances in stents, imaging and catheter technologies. Plain angioplasty balloons, embolic protection devices, guidewires and hospitals will see strong growth, while Asia Pacific is set to be the fastest-growi",
                "category": "company",
                "datetime": 1789727580,
                "headline": "Interventional Cardiology Devices Market by Type, End User - Global Forecast to 2031"
              },
              {
                "id": 142225420,
                "url": "https://finnhub.io/api/news?id=3f481a7df661c8f98de5df77adb029ad06c1cffb737eba375692d975ae4fc193",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE",
                "category": "company",
                "datetime": 1789642943,
                "headline": "Edwards Lifesciences Sees TAVR Expansion, $2B TMTT Opportunity Ahead"
              },
              {
                "id": 142198959,
                "url": "https://finnhub.io/api/news?id=568783958075196b65740530debea12cb32f6534984a1b55719ef4f7c7471b7c",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.",
                "category": "company",
                "datetime": 1789585501,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 142197673,
                "url": "https://finnhub.io/api/news?id=30298a7b867fc3d1c8506990163ac5c9a3e40dd91ed64cc86b4796e19106bb06",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.",
                "category": "company",
                "datetime": 1789576500,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 142197743,
                "url": "https://finnhub.io/api/news?id=9b56623bc1072bd0de84cf62140ea790418711ad90edb1c273a8b5b42899b3ea",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "Edwards Lifesciences Corporation (EW) Deutsche Bank 2026 Healthcare Summit September 16, 2026 10:00 AM EDTCompany ParticipantsBernard Zovighian - CEO &...",
                "category": "company",
                "datetime": 1789563698,
                "headline": "Edwards Lifesciences Corporation (EW) Presents at Deutsche Bank 2026 Healthcare Summit Transcript"
              },
              {
                "id": 142163400,
                "url": "https://finnhub.io/api/news?id=712ca2141d14c09265822f1d9ad959df7e8bcf8783050923b13cc6f764bc4616",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "EW",
                "summary": "Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.57% on an annualized basis producing an average annual return of 16.73%. Currently, Edwards Lifesciences has a market capitalization",
                "category": "company",
                "datetime": 1789410618,
                "headline": "$100 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 142089165,
                "url": "https://finnhub.io/api/news?id=730ee985635cf2cb4174a462055018cf2fb3f8c1a7fa9df3fbe6e9889f37215f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1789153501,
                "headline": "Top S&P500 movers in Friday's session"
              },
              {
                "id": 142087699,
                "url": "https://finnhub.io/api/news?id=d008f77c83c23655aa93afca754d58b5809bf8c51f25fceeb225e41d40e1da58",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "EW",
                "summary": "Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.",
                "category": "company",
                "datetime": 1789144501,
                "headline": "Stay informed with the top movers within the S&P500 index on Friday."
              },
              {
                "id": 142088351,
                "url": "https://finnhub.io/api/news?id=5b13fc1b3e7da5df89780e934cc69daf787479d049e9ace50f6b66fc848fab41",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "The Centers for Medicare and Medicaid Services’ policy update extends Medicare coverage to severe aortic stenosis patients without symptoms, a change that analysts said will especially benefit Edwards Lifesciences.",
                "category": "company",
                "datetime": 1789128882,
                "headline": "CMS expands TAVR Medicare coverage to asymptomatic patients"
              },
              {
                "id": 142087525,
                "url": "https://finnhub.io/api/news?id=e1db2e5e73f465a1830dd146275cae0b8f5ac8ba767db9834b8b45a100a239d4",
                "image": "",
                "source": "Benzinga",
                "related": "EW",
                "summary": "BTIG  analyst Marie Thibault   reiterates Edwards Lifesciences (NYSE:EW) with a Buy and maintains $110 price target.",
                "category": "company",
                "datetime": 1789106253,
                "headline": "BTIG Reiterates Buy on Edwards Lifesciences, Maintains $110 Price Target"
              },
              {
                "id": 142066287,
                "url": "https://finnhub.io/api/news?id=23a1bbb562bdd05c03a4889d81973e892c03106cf45f4948eabd82d8e4834812",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "IRVINE, Calif., September 10, 2026--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):",
                "category": "company",
                "datetime": 1789076940,
                "headline": "Edwards Lifesciences Comments on TAVR National Coverage Decision"
              },
              {
                "id": 141951037,
                "url": "https://finnhub.io/api/news?id=da6fa2d576819e8545394b26df1efa3f372cede55f32e64c0297eaa73a0dda31",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Despite lagging behind the Dow over the past 12 months, Edwards Lifesciences continues to receive a highly bullish outlook from Wall Street analysts.",
                "category": "company",
                "datetime": 1788859207,
                "headline": "Is Edwards Lifesciences Stock Underperforming the Dow?"
              },
              {
                "id": 141758077,
                "url": "https://finnhub.io/api/news?id=f0abeae7b345fcf63f4ae44fa3cce64a78b15eb65c0eec0d640baaff2b2fd7c4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2249179691/image_2249179691.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "EW",
                "summary": "Baron Asset Fund initiated a position in Edwards Lifesciences due to its dominant heart valve market share. Read the full analysis for more details.",
                "category": "company",
                "datetime": 1788750600,
                "headline": "Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound"
              },
              {
                "id": 141437930,
                "url": "https://finnhub.io/api/news?id=363996b5598cdc6cbd4a9ff5b8357ca4a6e2dfb3b9ccf4040974e9945cfc3d7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "EW",
                "summary": "Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535817,
                "headline": "Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 3,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.6,
            "source_article_count": 20,
            "discarded_article_count": 17
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 15.8,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.1,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.1,
            "vcp_reason": "波幅收縮(10.7%→6.1%)；靠近20日高位；升放量(近10日4日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 3233746.6666666665,
              "down_days": 4,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 3681740,
              "avg_vol_20": 3468985,
              "avg_vol_30": 3233746.6666666665,
              "range_pct_10": 0.06071638285378745,
              "range_pct_20": 0.09066353493834407,
              "range_pct_30": 0.10733998825601879,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": false,
              "up_expand_days": 4,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 1.1385369292997596,
              "dist_to_20d_high": 0.06970392221129679,
              "down_shrink_days": 1,
              "breakout_level_20d": 91.53,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.5656455142231949
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 0,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 1,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.401644157369348,
              "turnoverUsdM": 205.07526,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.EW",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 81.06,
            "strength_details": {
              "ma_score": 1,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 4.8,
            "take_profit_price": 89.4075,
            "target_multiplier": 1.6,
            "technical_strength": 1.15,
            "take_profit_percent": 5
          },
          "positionPoints": 1.4,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.803288314738696,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": true,
    "missingFields": [],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 71.43,
    "atr": {
      "atr": 2.045,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.4
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -91.45
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0486
    },
    "kdj": {
      "d": 37.88,
      "j": 4.83,
      "k": 26.87,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 43.57
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 2,
      "trend": "資金流出",
      "value": -11782200,
      "recentSlope": -413460,
      "previousSlope": 769270
    },
    "rsi": 48.64,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 85.078,
      "position": "SAR喺價下",
      "distancePct": 0.08,
      "previousTrend": "上升"
    },
    "ma50": 88.4808,
    "macd": {
      "macd": -0.8444324260795071,
      "trend": "看跌",
      "signal": -0.6991735014844324,
      "histogram": -0.14525892459507472
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 86.9788,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.69,
      "score": 2,
      "avgVolume": 3497200,
      "currentVolume": 2408400
    },
    "derived": {
      "ma20": 86.926,
      "ma50": 88.4808,
      "prevClose": 85.19,
      "avgVolume10": 3497190,
      "avgVolume20": 3497200,
      "changePercent": -0.05,
      "avgVolumeForScore": 3497200
    },
    "ma_cross": {
      "ma20": 86.926,
      "ma50": 88.4808,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "熊勢",
      "score": 0,
      "prevMa20": 87.1575,
      "prevMa50": 88.4542,
      "spreadPct": 1.76,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 83.9725,
      "upper": 89.8795,
      "position": "中間"
    },
    "rsi_short": 44.51,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.69
    }
  }
}

{
  "close": 85.15,
  "volume": 2408400,
  "changePercent": -0.05
}